Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04725994 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

A Phase 1 study of Gastric Cancer, sponsored by Idience Co..

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
14
Study locations

NCT04725994 is a Phase 1 study of Gastric Cancer that is actively recruiting participants, run by Idience Co.. The registered enrollment target is 100 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (69% lower). The trial reports 14 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04725994, a Phase 1 study of Gastric Cancer, is actively recruiting participants, sponsored by Idience Co..

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
14
Study locations

Study Summary

This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.

Conditions Studied

Gastric Cancer

Interventions

  • DRUG IDX-1197+XELOX
  • DRUG IDX-1197+Irinotecan

Study Locations (14)

Other

  • Beijing Cancer Hospital - Beijing
  • The Sixth Affiliated Hospital of Sun Yat-Sen University - Guangzhou
  • Shanghai East Hospital - Shanghai
  • Dong-A University Hospital - Busan
  • Seoul National University Bundang Hospital - Seongnam
  • Korea University Anam Hospital - Seoul
  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Seoul National University Hospital - Seoul
  • Severance Hospital - Yonsei Cancer Center - Seoul

California

  • USC Norris Comp. Cancer Ctr Hospital - Los Angeles

Louisiana

  • Hematology Oncology Clinic Baton Rouge / Sarah Cannon - Baton Rouge

Massachusetts

  • Dana Farber Cancer Institute - Boston

New Jersey

  • Astera Cancer Care - East Brunswick

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-06-28
Est. Completion 2026-06-30
Phase Phase 1

Sponsor

Idience Co.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04725994

The ClinicalTrials.gov registry entry for NCT04725994 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Idience Co., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which IDX-1197+XELOX is the first listed.

NCT04725994 reports 14 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Louisiana.

Frequently Asked Questions

What is clinical trial NCT04725994 about?

NCT04725994 is a clinical study titled "Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer". This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.

What is the current status of trial NCT04725994?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2021-06-28. Estimated completion is 2026-06-30.

What conditions does trial NCT04725994 study?

This clinical trial studies the following conditions: Gastric Cancer.

What interventions are being tested in trial NCT04725994?

The interventions under investigation include: IDX-1197+XELOX (DRUG), IDX-1197+Irinotecan (DRUG).

Who is sponsoring clinical trial NCT04725994?

This trial is sponsored by Idience Co., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04725994 being conducted?

This trial has 14 study locations across California, Louisiana, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.